Table 13: Clinical evidence profile: Comparison 1: intrathecal baclofen, post-operative versus pre-operative outcomes

Quality assessment						No of patients		Effect				
No of studie s	Design	Risk of bias	Inconsistency	Indirectness	Imprecisio n	Other consideration s	Intrath ecal baclof en	Pre- operat ive	Relative (95% CI)	Absolute	Quality	Importance
Walking (follow-up 4 years; assessed with: household or community ambulation)												
1	observati onal studies	no serious risk of bias	no serious inconsistency	no serious indirectness	serious <sup>1</sup>	none	18/24 (75%)	15/24 (62.5 %)	RR 1.2 (0.82 to 1.77)	125 more per 1000 (from 113 fewer to 481 more)	VERY LOW	CRITICAL
Gross	motor funct	ion (follow	/-up 1 years; me	easured with: 0	SMFM score	range of score	es: 0-100;	Better in	ndicated by	y higher val	ues)	
1	observati onal studies	no serious risk of bias	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	9	9	-	MD 2.34 higher (2.34 lower to 7.02 higher)	VERY LOW	CRITICAL
Tone (ITB 100 micrograms bolus) upper extremity (follow-up 4 hours; measured with: Ashworth scale; range of scores: 1-5; Better indicated by lower values)												
1	randomis ed trials	no serious risk of bias	no serious inconsistency	serious <sup>3</sup>	serious <sup>4</sup>	none	8	8	-	MD 0.23 lower (0.71 lower to	LOW	CRITICAL

FINAL Management of abnormal muscle tone in adults aged 19 and over with cerebral palsy, including spasticity and associated movement disorders such as dystonia

Quality assessment							No of patients		Effect			
No of studie s	Design	Risk of bias	Inconsistency	Indirectness	Imprecisio n	Other consideration s	Intrath ecal baclof en	Pre- operat ive	Relative (95% CI)	Absolute	Quality	Importance
•	TB 100 mic values)	rograms b	olus) lower extr	emity (follow-ı	up 4 hours; n	neasured with:	Ashwortl	n scale; r	ange of so	ores: 1-5; E	Better ind	icated by
1	randomis ed trials	no serious risk of bias	no serious inconsistency	serious <sup>3</sup>	serious <sup>2</sup>	none	8	8	-	MD 1.4 lower (2.44 to 0.36 lower)	LOW	CRITICAL
Tone (	TB pump) l	ower extre	mity (follow-up	1 to 5 years; m	neasured wit	h: Ashworth sc	ale; rang	e of scor	es: 1-5; Be	etter indicat	ed by lov	ver values)
2	observati onal studies	no serious risk of bias	no serious inconsistency	serious <sup>5</sup>	serious <sup>2</sup>	none	38	38	-	MD ranged from 1.9 to 1.16 lower	VERY LOW	CRITICAL
Tone (	TB pump) ւ	ipper extre	emity (follow-up	1 years; meas	ured with: A	shworth scale;	range of	scores:	1-5; Better	indicated b	y lower v	values)
1	observati onal studies	no serious risk of bias	no serious inconsistency	no serious indirectness	serious <sup>2</sup>	none	13	13	-	MD 1.3 lower (2.15 to 0.45 lower)	VERY LOW	CRITICAL
Health	related qua	lity of life	not reported									
-	-	-	-	-	-	-	-	-	-	-		CRITICAL
Pain - ı	not reported	ı										
-	-	-	-	-	-	-	-	-	-	-		IMPORTA NT
Advers	e events (I1	B continu	ous infusion) (f	ollow-up 4 to 5	years; asse	ssed with: cath	eter or p	ump infe	ctions)			
2	observati onal studies	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>4</sup>	none	Rate ranged from 4.2 to 8%				VERY LOW	IMPORTA NT

**FINAL** 

Management of abnormal muscle tone in adults aged 19 and over with cerebral palsy, including spasticity and associated movement disorders such as dystonia

Quality assessment						No of patients		Effect				
No of studie s	Design	Risk of bias	Inconsistency	Indirectness	Imprecisio n	Other consideration s	Intrath ecal baclof en	Pre- operat ive	Relative (95% CI)	Absolute	Quality	Importance
3	observati onal studies	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>4</sup>	none	Rate ranged from 4.2% to 17%				VERY LOW	IMPORTA NT
Adverse events (ITB continuous infusion) (assessed with: Constipation)												
2	observati onal studies	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>4</sup>	none	Rate ranged from 4% to 15%				VERY LOW	IMPORTA NT
Adverse events (ITB continuous infusion) (follow-up 1 to 5 years; assessed with: Anxiety and depression)												
1	observati onal studies	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>4</sup>	none	Rate was 8%				VERY LOW	IMPORTA NT
Advers	se events (IT	B continue	ous infusion) (fo	ollow-up 1 year	rs; assessed	with: Seizures	)					
1	observati onal studies	serious <sup>1</sup>	no serious inconsistency	no serious indirectness	serious <sup>4</sup>	none	Rate was 15%				VERY LOW	IMPORTA NT
Satisfa	Satisfaction - not reported											
-	-	-	-	-	-	-	-	-	-	_		IMPORTA NT
Concurrent medications - not reported												
-	-	-	-	-	-	-	-	-	-	_		IMPORTA NT

CI: confidence interval; GMFM: Gross Motor Function Measure; HRQoL: Health related quality of life; ITB: intrathecal baclofen; MD: mean difference; MID: minimally important difference; RR: risk ratio

<sup>1</sup> No comparator

<sup>2</sup> Confidence interval includes one default MID threshold

<sup>3</sup> Intrathecal bolus injection rather than implanted pump

<sup>4</sup> Number of participants <400

<sup>5</sup> Extremity not reported in one of the studies